Baxalta Cancels Presentation at 34th Annual J.P. Morgan Healthcare Conference

BANNOCKBURN, Ill.--(BUSINESS WIRE)--

Baxalta (NYSE: BXLT) announced today that it will not present at the 34th Annual J.P. Morgan Healthcare Conference, which was previously scheduled for Wednesday, Jan. 13, 2016, at 4:30 p.m. Central Time.

The decision not to participate follows an announcement earlier today that Baxalta has entered an agreement to combine with Shire plc (LSE: SHP, NASDAQ: SHPG). The announcement press release can be found at http://newsroom.baxalta.com/press-releases/press-release-details/2016/Shire-to-Combine-with-Baxalta-Creating-the-Global-Leader-in-Rare-Diseases/default.aspx.

About Baxalta

Baxalta Incorporated (NYSE: BXLT) is a $6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Driven by passion to make a meaningful impact on patients’ lives, Baxalta’s broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy. The Baxalta Global Innovation and R&D Center is located in Cambridge, Massachusetts. Launched in 2015 following separation from Baxter International, Baxalta’s heritage in biopharmaceuticals spans decades. Baxalta’s therapies are available in more than 100 countries and it has advanced biological manufacturing operations across 12 facilities, including state-of-the-art recombinant production and plasma fractionation. Headquartered in Northern Illinois, Baxalta employs 16,000 employees worldwide.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160111006509/en/

Baxalta Media Relations
Geoffrey Mogilner, +1-224-940-8619
[email protected]
or
Baxalta Investor Relations
Mary Kay Ladone, +1-224-948-3371
[email protected]
or
Lorna Williams, +1-224-948-3511
[email protected]

Source: Baxalta Incorporated

You May Also Be Interested In

• Cogent Communications Holdings Securities Fraud Class Action Result of Undisclosed Demand and Backlog Issues and Approximately 29% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick
• Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
• Coinbase Selects Chainlink To Bring New Tokenized Stocks to Millions of DeFi Users